Cancer immunotherapy biotech Unum Therapeutics sets terms for $75 million IPO – Nasdaq
Nasdaq |
Cancer immunotherapy biotech Unum Therapeutics sets terms for $75 million IPO
Nasdaq Unum Therapeutics, which is developing antibody-coupled T cell immunotherapies for cancers, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14 … |
